Belgian UCB SA and British Cancer UK have started a second clinical study within their multi-year partnership to evaluate the safety and tolerable dose of UCB4594 in patients with advanced cancers.
https://european-biotechnology.com/wp-content/uploads/2024/10/UCB_HQ_Brussels.jpeg294922Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-10-28 07:59:122024-10-28 07:59:12Cancer UK/UCB collaboration: study with 2nd compound started